Disc Medicine reports early RESTORE-PV trial data for PV treatment
Tweet Send to a Friend
Disc Medicine, Inc. (NASDAQ: IRON) presented initial results from its RESTORE-PV Phase 2 trial of DISC-3405 in patients with polycythemia ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
